Ceasing medication can be a great attributer to the quality of life in AIH patients. Previous studies have pointed out that relapse is very frequent after stopping immunosuppresive medication, but not universal. It is therefore an option to withdraw treatment in a selected group of patients, but there are no indicators as to which patients are optimal candidates. In this study, patients without cirrosis, but with an excellent response to standard therapy and full resolution of biochemical and histological symptomps will be selected to withdraw treatment. The goal is to find the subgroup of patients that is amendable to safelycease medication.
For more information regarding this study, click here.